Cargando…
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
The epidermal growth factor receptor 2 (HER2) is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast cancers. Trastuzumab is a humanized monoclonal antibody that targets HER2. The majority of patients with metastatic breast cancer initially respond to trastuzumab, however, within...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE-Hindawi Access to Research
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262573/ https://www.ncbi.nlm.nih.gov/pubmed/22295219 http://dx.doi.org/10.4061/2011/352182 |